- GenLight Medical raises several hundred million yuan in a new round of financing as China’s neurotech sector takes off
- Sources say the company may seek another fundraising round before pursuing a listing next year
GenLight Medical (佳量脑科学), a Hangzhou-based medical technology company focused on brain-computer interfaces and neurosurgical devices, has completed a Series C financing round worth several hundred million yuan, according to people familiar with the matter.
Investors in the round included Chongqing-based Yufu Fund and Shanghai’s Chende Capital, among other institutions.
Following the latest financing, the company’s post-money valuation reportedly approached $1 billion.
One person close to the company said the management may consider another fundraising round this year before attempting an initial public offering in 2027, as investor interest in brain-computer interface technologies accelerates.
Founded in 2020 and headquartered in Hangzhou, GenLight develops medical devices and digital treatment technologies targeting neurological disorders including drug-resistant epilepsy, brain tumors and Parkinson’s disease.
The company has built four core technology platforms spanning brain-machine regulation systems, medical laser technologies, neural signal-processing chips and AI-assisted surgical software.
Its implantable systems are designed to interpret and regulate neural activity for the treatment of neurological diseases, while its software platform helps surgeons plan stereotactic procedures with greater precision.
GenLight has also been expanding its product pipeline and moving several core products toward commercialization.
Its flagship product, LaserRO, became China’s first domestically approved MRI-guided laser interstitial thermal therapy system for brain surgery after receiving clearance from China’s National Medical Products Administration in October 2025.
